Do approximately 90 % of individuals with hypermobile Ehlers‑Danlos syndrome exhibit mild, widespread autonomic dysfunction, and what are the recommended screening and first‑line non‑pharmacologic treatments?

Autonomic Dysfunction Prevalence in hEDS

The claim that 90% of hEDS patients have widespread but mild autonomic failure is supported by recent research, though current clinical guidelines emphasize targeted rather than universal screening for autonomic dysfunction. 1

Evidence for the 90% Prevalence Claim

A 2025 retrospective case-control study of 270 hEDS patients found that widespread but mild autonomic failure was present in 90% of hEDS patients on autonomic testing, with common complaints (prevalence >90%) including orthostatic sudomotor, vasomotor, gastrointestinal symptoms, and pain. 1 This study also documented:

• Reduced orthostatic cerebral blood flow velocity in 79% of patients 1
• Small fiber neuropathy in 64% using structural criteria and 82% using combined structural and functional criteria 1
• Postural tachycardia syndrome (POTS) in 33% 1

Additional research supports high rates of autonomic dysfunction, with a 2014 study showing 74% of hEDS patients experienced orthostatic intolerance compared to 34% of controls, characterized by increased sympathetic activity at rest and reduced sympathetic reactivity to stimuli. 2

Current Guideline Recommendations on Screening

The 2025 AGA Clinical Practice Update explicitly states that universal testing for POTS/autonomic dysfunction in all patients with hEDS is NOT supported by current evidence. 3 Instead:

• Screening should be targeted to patients presenting with clinical manifestations of orthostatic intolerance (palpitations, dizziness, presyncope, syncope, lightheadedness) 3
• Referral for autonomic testing should be considered in patients with hEDS and refractory GI symptoms who report orthostatic intolerance after exclusion of medication side effects and appropriate lifestyle modifications have been attempted 3

Clinical Red Flags Warranting Autonomic Evaluation

Look specifically for: 3, 4

• Symptoms relieved by sitting or lying down
• Exacerbation with food ingestion, exertion, or heat exposure
• Palpitations and tachycardia when standing
• Gastrointestinal dysmotility symptoms
• Bladder dysfunction
• Thermoregulatory disturbances

First-Line Non-Pharmacologic Treatments

For confirmed POTS/autonomic dysfunction in hEDS, the AGA recommends a specific three-pronged conservative approach: 3

1. Fluid and Salt Intake Optimization

• Increase fluid intake substantially 3
• Increase dietary salt intake 3

2. Exercise Training

• Structured cardiovascular fitness programs 3
• Focus on maintaining physical conditioning despite symptoms 5

3. Compression Garments

• Use of compression stockings or abdominal binders 3

4. Environmental Trigger Management

• Avoid prolonged standing 5
• Manage exposure to heat 5
• Address dehydration proactively 5

Important Clinical Caveats

The disconnect between research findings (90% prevalence) and guideline recommendations (targeted screening) reflects: 3

• Limited experimental evidence of biological mechanisms linking hEDS and dysautonomia
• Potential confounding by medications (stimulants, centrally acting agents) 3
• Inconsistent application of 2017 hEDS diagnostic criteria in many studies 3
• The fact that many patients with mild autonomic dysfunction may not require specific intervention beyond symptom management

Pharmacological treatment should be reserved for patients with moderate-to-severe impairment of daily function who have inadequate response to conservative measures, requiring integrated care from multiple specialties including cardiology and neurology. 3, 5

The evidence suggests that while autonomic testing may reveal abnormalities in the vast majority of hEDS patients, clinical screening should focus on those with symptomatic orthostatic intolerance rather than pursuing universal autonomic testing. 3